Clinical Report: Immunometabolic Pathways and Potential Therapeutic Targets in MASH
Overview
Revise to clarify the distinction between MASH and MASLD, emphasizing the implications of limited pharmacological options.
Background
MASH represents a significant global health challenge, paralleling the rise in obesity and metabolic syndrome. It is a subtype of metabolic dysfunction-associated steatotic liver disease (MASLD) that can progress to severe liver conditions, including cirrhosis and hepatocellular carcinoma. Understanding the immunometabolic mechanisms underlying MASH is crucial for developing effective treatments.
Data Highlights
No numerical data available in the source material.
Key Findings
MASH is characterized by hepatic steatosis, inflammation, and potential progression to cirrhosis and hepatocellular carcinoma.
Insulin resistance is a key factor in the pathogenesis of MASH, promoting lipid accumulation in the liver.
Current therapeutic strategies are limited, necessitating the exploration of immunometabolic pathways for drug development.
Emerging targets include PPARs, FXR, and the GLP-1/FGF21 axis, among others.
Precision medicine approaches focusing on immunometabolic networks may enhance treatment efficacy.
Clinical Implications
Expand on specific management strategies and the importance of early identification.
Conclusion
Reinforce the need for multi-target interventions with specific examples from the source.
